{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T03:24:34Z","timestamp":1770089074254,"version":"3.49.0"},"update-to":[{"DOI":"10.1002\/14651858.cd001908.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T00:00:00Z","timestamp":1571011200000}}],"reference-count":46,"publisher":"Wiley","issue":"10","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001908.pub4","type":"journal-article","created":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T11:17:56Z","timestamp":1571051876000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Tiagabine add-on therapy for drug-resistant focal epilepsy"],"prefix":"10.1002","volume":"2019","author":[{"given":"Rebecca","family":"Bresnahan","sequence":"first","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Lower Lane Liverpool UK L9 7LJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsty J","family":"Martin-McGill","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Lower Lane Liverpool UK L9 7LJ"},{"name":"University of Chester; Department of Clinical Sciences and Nutrition; Faculty of Medicine, Dentistry and Life Sciences Chester UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane L","family":"Hutton","sequence":"additional","affiliation":[{"name":"University of Warwick; Department of Statistics; Coventry UK CV4 7AL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony G","family":"Marson","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Lower Lane Liverpool UK L9 7LJ"},{"name":"The Walton Centre NHS Foundation Trust; Liverpool UK"},{"name":"Liverpool Health Partners; Liverpool UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,10,14]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD001908.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1046\/j.1528-1157.2001.36500.x","article-title":"Tiagabine: efficacy and safety in adjunctive treatment of partial seizures","volume":"42","author":"Crawford","year":"2001","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD001908.pub4-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.yebeh.2005.01.002","article-title":"Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy","volume":"6","author":"Fritz","year":"2005","journal-title":"Epilepsy & Behavior"},{"issue":"3","key":"10.1002\/14651858.CD001908.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0920-1211(96)00084-8","article-title":"Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy","volume":"25","author":"Kalviainen","year":"1996","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD001908.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0920-1211(97)00082-X","article-title":"A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures","volume":"30","author":"Kalviainen","year":"1998","journal-title":"Epilepsy Research"},{"issue":"1","key":"10.1002\/14651858.CD001908.pub4-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0920-1211(95)00006-V","article-title":"Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial","volume":"21","author":"Richens","year":"1995","journal-title":"Epilepsy Research"},{"issue":"1","key":"10.1002\/14651858.CD001908.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1059-1311(05)80160-8","article-title":"Neuropsychological effects of tiagabine, a potential new antiepileptic drug","volume":"3","author":"Sveinbjornsdottir","year":"1994","journal-title":"Seizure"},{"key":"10.1002\/14651858.CD001908.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archneur.1997.00550170069016","article-title":"Tiagabine therapy for complex partial seizures: a dose-frequency study","volume":"54","author":"Sachdeo","year":"1997","journal-title":"Archives of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD001908.pub4-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1212\/WNL.48.4.1025","article-title":"Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy","volume":"48","author":"Dodrill","year":"1997","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001908.pub4-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/archneur.55.1.56","article-title":"Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial","volume":"55","author":"Uthman","year":"1998","journal-title":"Archives of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD001908.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.seizure.2004.09.002","article-title":"A randomised open-label study of tiagabine given two or three times daily in refractory epilepsy","volume":"14","author":"Arroyo","year":"2005","journal-title":"Seizure"},{"issue":"1","key":"10.1002\/14651858.CD001908.pub4-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0896-6974(94)00015-R","article-title":"Efficacy and tolerability of tiagabine: results of an add-on study in patients with refractory partial seizures","volume":"8","author":"Bauer","year":"1995","journal-title":"Journal of Epilepsy"},{"issue":"4","key":"10.1002\/14651858.CD001908.pub4-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1212\/WNL.48.4.1032","article-title":"A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures","volume":"48","author":"Gustavson","year":"1997","journal-title":"Neurology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD001908.pub4-BIB0013|cit13","first-page":"S147","article-title":"Single-blind study of safety, tolerability and preliminary efficacy of tiagabine as adjunctive treatment of children with epilepsy","volume":"36","author":"Uldall","year":"1995","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD001908.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2165\/00003495-199855030-00013","article-title":"Tiagabine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy","volume":"55","author":"Adkins","year":"1998","journal-title":"Drugs"},{"issue":"11","key":"10.1002\/14651858.CD001908.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1528-1157.2000.tb00110.x","article-title":"Quality of life and behavioural outcome measures in randomized controlled trials of antiepileptic drugs: a systematic review of reporting standards","volume":"41","author":"Baker","year":"2000","journal-title":"Epilepsia"},{"issue":"10","key":"10.1002\/14651858.CD001908.pub4-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1528-1157.1998.tb01295.x","article-title":"Neuropsychological outcomes in randomized controlled trials of antiepileptic drugs: a systematic review of methodology and reporting standards","volume":"39","author":"Cochrane","year":"1998","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001908.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0140-6736(95)91208-8","article-title":"Remission of epilepsy: results from the national general practice study of epilepsy","volume":"346","author":"Cockerell","year":"1995","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD001908.pub4-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"Proposal for revised classification of epilepsies and epileptic syndromes","volume":"30","author":"Commission on Classification and Terminology of the International League Against Epilepsy","year":"1989","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD001908.pub4-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1212\/WNL.48.4.1025","article-title":"Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy","volume":"48","author":"Dodrill","year":"1997","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD001908.pub4-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1756285611417920","article-title":"The cognitive impact of antiepileptic drugs","volume":"4","author":"Eddy","year":"2011","journal-title":"Therapeutic advances in neurological disorders"},{"issue":"3","key":"10.1002\/14651858.CD001908.pub4-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","article-title":"Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies","volume":"88","author":"Fiest","year":"2017","journal-title":"Neurology"},{"issue":"2-3","key":"10.1002\/14651858.CD001908.pub4-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0014-2999(92)90748-S","article-title":"The gamma-aminobutyric acid (GABA) uptake inhibitor, tiagabine, increases extracellular brain levels of GABA in awake rats","volume":"220","author":"Fink-Jensen","year":"1992","journal-title":"European Journal of Pharmacology"},{"key":"10.1002\/14651858.CD001908.pub4-BIB0023|cit23","unstructured":"Food Drug Administration Approval Letter www.accessdata.fda.gov\/drugsatfda_docs\/nda\/97\/020646ap_gabitril_apltr.pdf"},{"key":"10.1002\/14651858.CD001908.pub4-BIB0024|cit24","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro Guideline Development Tool 2015"},{"issue":"6","key":"10.1002\/14651858.CD001908.pub4-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1528-1157.1995.tb02575.x","article-title":"Pharmacokinetics of tiagabine, a gamma-aminobutyric acid-uptake inhibitor, in healthy subjects after single and multiple doses","volume":"36","author":"Gustavson","year":"1995","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD001908.pub4-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1528-1157.1993.tb02586.x","article-title":"Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984","volume":"34","author":"Hauser","year":"1993","journal-title":"Epilepsia"},{"issue":"1","key":"10.1002\/14651858.CD001908.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1212\/01.wnl.0000438226.10353.1c","article-title":"The questionable use of unequal allocation in confirmatory trials","volume":"82","author":"Hey","year":"2014","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001908.pub4-BIB0028|cit28","unstructured":"Higgins JPT Green S editor(s) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"9","key":"10.1002\/14651858.CD001908.pub4-BIB0029|cit29","first-page":"1922","article-title":"Definition of drug resistant epilepsy. Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD001908.pub4-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0920-1211(96)00084-8","article-title":"Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy","volume":"25","author":"Kalviainen","year":"1996","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD001908.pub4-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD001908.pub4-BIB0032|cit32","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD001908.pub4-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1111\/j.1528-1157.1995.tb06009.x","article-title":"Tiagabine: the safety landscape","volume":"36 Suppl 6","author":"Leppik","year":"1995","journal-title":"Epilepsia"},{"issue":"7066","key":"10.1002\/14651858.CD001908.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/bmj.313.7066.1169","article-title":"New antiepileptic drugs: a systematic review of their efficacy and tolerability","volume":"313","author":"Marson","year":"1996","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD001908.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1528-1157.1997.tb01251.x","article-title":"The new antiepileptic drugs: a systematic review of their efficacy and tolerability","volume":"38","author":"Marson","year":"1997","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001908.pub4-BIB0036|cit36","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-3242-6","volume-title":"Generalized Linear Models","author":"McCullagh","year":"1989"},{"issue":"9","key":"10.1002\/14651858.CD001908.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/j.1528-1157.1997.tb01478.x","article-title":"Antiepileptic effects of tiagabine, a selective GABA uptake inhibitor, in the rat kindling model of temporal lobe epilepsy","volume":"38","author":"Morimoto","year":"1997","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001908.pub4-BIB0038|cit38","article-title":"Tiagabine","volume-title":"Mechanisms of Action in Antiepileptic Drugs","author":"Ostergaard","year":"1995"},{"issue":"5","key":"10.1002\/14651858.CD001908.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/jnnp.61.5.433","article-title":"Epidemiology of the epilepsies","volume":"61","author":"Sander","year":"1996","journal-title":"Journal of Neurology, Neurosurgery, & Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD001908.pub4-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001908.pub4-BIB0041|cit41","unstructured":"Sch\u00fcnemann H Bro\u017cek J Guyatt G Oxman A editor(s) GRADE handbook for grading quality of evidence and strength of recommendations (updated October 2013). Grade Working Group, 2013 Available from www.guidelinedevelopment.org\/handbook"},{"key":"10.1002\/14651858.CD001908.pub4-BIB0042|cit42","unstructured":"Smith MJ Generalised linear models Statistical Analysis Handbook 2018 edition www.statsref.com\/HTML\/index.html?glim.html"},{"issue":"1","key":"10.1002\/14651858.CD001908.pub4-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1059-1311(05)80160-8","article-title":"Neuropsychological effects of tiagabine, a potential new antiepileptic drug","volume":"3","author":"Sveinbjornsdottir","year":"1994","journal-title":"Seizure"},{"issue":"3","key":"10.1002\/14651858.CD001908.pub4-BIB0044|cit44","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001908","article-title":"Tiagabine add-on for drug-resistant partial epilepsy","author":"Pereira","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"5","key":"10.1002\/14651858.CD001908.pub4-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001908.pub2","article-title":"Tiagabine add-on for drug-resistant partial epilepsy","author":"Pulman","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD001908.pub4-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001908.pub3","article-title":"Tiagabine add-on for drug-resistant partial epilepsy","author":"Pulman","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD001908.pub4\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,7]],"date-time":"2021-11-07T19:46:30Z","timestamp":1636314390000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001908.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,10,14]]},"references-count":46,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001908.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,14]]}}}